Tuesday, February 06, 2024 8:42:34 AM
https://finance.yahoo.com/news/tscan-therapeutics-expands-clinical-team-120000514.html
TScan Therapeutics, Inc.
WALTHAM, Mass., Feb. 06, 2024 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biopharmaceutical company focused on the development of T cell receptor (TCR)-engineered T cell therapies (TCR-T) for the treatment of patients with cancer, today announced the appointment of Dawn Pinchasik, M.D., M.S., as Vice President, Clinical Development. Dr. Pinchasik brings to TScan over a decade of experience in clinical development across the pharmaceutical and biotechnology industry.
“We are pleased to welcome Dawn to TScan at such an exciting time in the Company’s evolution,” said Debora Barton, M.D., Chief Medical Officer. “Her expertise in cell and gene therapy clinical development and experience with regulatory interactions, most recently at ElevateBio, will be crucial as we advance our clinical-stage pipeline across heme malignancies and solid tumors. We remain on track to dose the first patient in the Phase 1 solid tumor study in the first quarter of 2024, and I look forward to working closely with Dawn as we advance this program through the clinic.”
“I am excited to join the TScan team as we work towards our mission of delivering life-changing therapies to patients battling a variety of solid tumors and heme malignancies,” added Dr. Pinchasik. “I am eager to harness my past experiences and work closely with the clinical team to advance this scientifically compelling pipeline and improve patient outcomes through the development of these novel therapies.”
Prior to joining TScan, Dr. Pinchasik was the Senior Director, Early Development at ElevateBio, LLC, where she supported the internal pipeline and partnered programs for ElevateBio and the wholly owned subsidiary, Life Edit Therapeutics Inc. Before joining ElevateBio, Dr. Pinchasik was a Senior Medical Director at Rubius Therapeutics, Inc., where she supported all clinical-stage pipeline products for the company’s cell therapy platform, including the launch of its first two clinical trials. Prior to that, Dr. Pinchasik was the Medical Director at Aileron Therapeutics, Inc., where she worked closely with the chief medical officer and led the development of protocols and regulatory documents. Earlier in her career, Dr. Pinchasik held roles of increasing responsibility at Onyx Pharmaceuticals, Inc. (Onyx) and later at Amgen, Inc., following its acquisition of Onyx in 2014. She completed a fellowship in pediatric hematology/oncology at Cincinnati Children’s Hospital Medical Center in 2013 and residency in pediatrics at Children’s Hospital of Pittsburgh in 2010. Dr. Pinchasik holds an M.D. from Drexel University College of Medicine, and an M.S., Clinical and Translational Research, from the University of Cincinnati.
About TScan Therapeutics, Inc.
TScan is a clinical-stage biopharmaceutical company focused on the development of T cell receptor (TCR)-engineered T cell therapies (TCR-T) for the treatment of patients with cancer. The Company’s lead TCR-T therapy candidates, TSC-100 and TSC-101, are in development for the treatment of patients with hematologic malignancies to eliminate residual disease and prevent relapse after allogeneic hematopoietic cell transplantation. The Company is also developing multiplexed TCR-T therapy candidates for the treatment of various solid tumors. The Company has developed and continues to build its ImmunoBank, the Company’s repository of therapeutic TCRs that recognize diverse targets and are associated with multiple HLA types, to provide customized multiplexed TCR-T therapies for patients with a variety of cancers.
Recent TCRX News
- TScan Therapeutics Announces Upcoming Presentations at the 2024 American Society of Clinical Oncology Annual Meeting • GlobeNewswire Inc. • 04/24/2024 08:05:34 PM
- TScan Therapeutics Announces Exercise of Underwriters' Option to Purchase Additional Shares • GlobeNewswire Inc. • 04/24/2024 03:03:30 PM
- TScan Therapeutics Announces Upcoming Presentations at the American Society of Gene and Cell Therapy 27th Annual Meeting • GlobeNewswire Inc. • 04/22/2024 09:01:23 PM
- TScan Therapeutics Announces Closing of Upsized Public Offering • GlobeNewswire Inc. • 04/19/2024 02:05:23 PM
- TScan Therapeutics Announces Pricing of Upsized $150 Million Public Offering • GlobeNewswire Inc. • 04/17/2024 04:30:57 AM
- TScan Therapeutics Announces Launch of $125 Million Proposed Public Offering • GlobeNewswire Inc. • 04/16/2024 08:25:22 PM
- TScan Therapeutics Provides Clinical Pipeline Update and Highlights Near-Term Priorities • GlobeNewswire Inc. • 04/16/2024 08:01:00 PM
- TScan Therapeutics Appoints Seasoned Hematology and Oncology Expert Chrystal U. Louis, M.D., M.P.H., as Chief Medical Officer • GlobeNewswire Inc. • 04/08/2024 12:00:00 PM
- TScan Therapeutics Announces Upcoming Presentation at the 23rd Annual Needham Virtual Healthcare Conference • GlobeNewswire Inc. • 04/02/2024 11:00:00 AM
- Form S-3 - Registration statement under Securities Act of 1933 • Edgar (US Regulatory) • 03/06/2024 09:11:41 PM
- Form S-8 - Securities to be offered to employees in employee benefit plans • Edgar (US Regulatory) • 03/06/2024 09:05:39 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 03/06/2024 12:30:34 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/06/2024 12:15:10 PM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 02/14/2024 09:45:41 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/29/2024 12:15:03 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/11/2023 01:00:03 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/07/2023 12:15:01 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/09/2023 12:30:23 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/09/2023 12:15:08 PM
- TScan Gets FDA Clearance of Investigational New Drug Application for Cancer Treatment • Dow Jones News • 08/29/2023 12:02:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/10/2023 11:30:55 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/10/2023 11:15:53 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/24/2023 11:39:09 PM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 07/24/2023 11:31:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/29/2023 12:30:28 PM
Bantec Reports an Over 50 Percent Increase in Sales and Profits in Q1 2024 from Q1 2023 • BANT • Apr 25, 2024 10:00 AM
Cannabix's Breath Logix Alcohol Device Delivers Positive Impact to Private Monitoring Agency in Montana, USA • BLO • Apr 25, 2024 8:52 AM
Kona Gold Beverages, Inc. Announces Name Change to NuVibe, Inc. and Initiation of Ticker Symbol Application Process • KGKG • Apr 25, 2024 8:30 AM
Axis Technologies Group and Carbonis Forge Ahead with New Digital Carbon Credit Technology • AXTG • Apr 24, 2024 3:00 AM
North Bay Resources Announces Successful Equipment Test at Bishop Gold Mill, Inyo County, California • NBRI • Apr 23, 2024 9:41 AM
Epazz, Inc.: CryObo, Inc. solar Bitcoin operations will issue tokens • EPAZ • Apr 23, 2024 9:20 AM